Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 350Polycystic Ovary Syndrome 38Endometrial Neoplasms 22Neoplasm Metastasis 21Ovarian Neoplasms 16Neoplasms 11Infertility 11Fallopian Tube Neoplasms 8Advanced Breast Cancer 8Triple Negative Breast Neoplasms 7Carcinoma, Intraductal, Noninfiltrating 7Carcinoma, Ductal, Breast 7Breast Neoplasms, Male 7Recurrence 6Osteoporosis 6Carcinoma, Lobular 6Breast Diseases 6Breast Carcinoma In Situ 6Prostatic Neoplasms 5Leiomyoma 4Infertility, Female 4Hereditary Sensory and Autonomic Neuropathies 4Breast Cancer Metastatic 4Neoplasms, Hormone-Dependent 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2

Interventions

Methotrexate 4Vacuum Curettage 3merphos 2Drug Therapy 2Dactinomycin 2Vitamin B Complex 1Suction 1Pemetrexed 1Leucovorin 1Letrozole 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hydatidiform Mole × Letrozole × Clear all
NCT05203562 2022-07-12

Letrozole as a Prophylaxis From GTN for Complete Mole Patients

Zagazig University

Phase 2/3 Unknown
200 enrolled
Gynecologic

Hydatidiform Mole, Gestational Trophoblastic Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡